TNFRSF11A and osteoporosis: The interaction between the receptor activator of nuclear factor‐κB ligand (RANKL) and its receptor RANK is known to regulate osteoclastogenesis in bone remodelling and has become an important therapeutic target for the treatment of osteoporosis.